Valeriano-Marcet J, Kerr L D, Spiera H
Department of Medicine, Mount Sinai Medical Center, New York, NY 10029.
J Rheumatol. 1992 May;19(5):729-31.
Previous investigators have reported the presence of complement activation products in scleroderma. Using an assay consisting of isoelectric focussing followed by immunofixation (IEF/IF) for alternative pathway activation product Ba, and an ELISA for C3d that we developed for evaluating lupus plasmas, we assayed 48 plasmas from patients with diffuse cutaneous scleroderma, 16 patients with the limited CREST variant, 2 patients with mixed connective tissue disease (MCTD) and 4 patients with Raynaud's disease. Ba was not detected in any patient's plasma. Only one plasma from a patient with CREST contained elevated levels of C3d. We cannot reconcile the absence of B activation products in our patients with scleroderma with the results of the previous report, and conclude that further studies are necessary.
先前的研究人员报告称硬皮病患者体内存在补体激活产物。我们采用一种检测方法，该方法包括先进行等电聚焦，然后进行免疫固定（IEF/IF）以检测替代途径激活产物Ba，以及我们开发的用于评估狼疮血浆的C3d酶联免疫吸附测定（ELISA），对48例弥漫性皮肤型硬皮病患者、16例有限型CREST变异患者、2例混合性结缔组织病（MCTD）患者和4例雷诺病患者的血浆进行了检测。在任何患者的血浆中均未检测到Ba。仅1例CREST患者的血浆中C3d水平升高。我们无法将硬皮病患者体内B激活产物的缺失与先前报告的结果相协调，并得出结论认为有必要进行进一步研究。
